Skip to content
ppharmaranks
Menu
Class IITerminated

Fosaprepitant for Injection 150 mg per vial recall

FDA recall D-0262-2024 · initiated Jan 10, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jan 31, 2024How we research

BE PHARMACEUTICALS AG recalled Fosaprepitant for Injection 150 mg per vial in Jan 2024 — an FDA Class II recall (D-0262-2024) because Lack of Sterility Assurance: Aseptic process simulation failure.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Lack of Sterility Assurance: Aseptic process simulation failure.

Sterility could not be assured

The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

lot #13D012AA, Exp: 08/31/2025

Quantity recalled: 22,176 Vials

Details

Product
Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution and dilution, Single Dose Vial, Rx Only, Distributed by BE Pharmaceuticals Inc. 203 New Edition Court Cary, NC 27511, Made in India, NDC 71839-104-01.
Recalling company
Be Pharms
Classification
Class II
Status
Terminated
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jan 10, 2024
FDA report date
Jan 31, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Fosaprepitant for Injection 150 mg per vial recalled?
BE PHARMACEUTICALS AG recalled Fosaprepitant for Injection 150 mg per vial in Jan 2024 — an FDA Class II recall (D-0262-2024) because Lack of Sterility Assurance: Aseptic process simulation failure. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Fosaprepitant for Injection 150 mg per vial recalled?
Per the FDA enforcement record, the reason for recall D-0262-2024 was: Lack of Sterility Assurance: Aseptic process simulation failure.
Is a recalled Fosaprepitant for Injection 150 mg per vial dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Fosaprepitant for Injection 150 mg per vial are affected?
Distributed: Nationwide in the USA. The recall covers these lots — lot #13D012AA, Exp: 08/31/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0262-2024.

Source: openFDA Drug Enforcement record D-0262-2024

← All drug recalls